Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00126594 · ClinicalTrials.gov registry record · Phase 2

Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

A Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT00126594 is a Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 80 participants, below the 201-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00126594, a Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This randomized phase II trial is studying sorafenib and interferon alfa-2b to see how well they work compared to sorafenib alone in treating patients with metastatic kidney cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib and interferon alfa-2b may also block blood flow to the tumor. Giving sorafenib together with interferon alfa-2b may kill more tumor cells.

Conditions Studied

Clear Cell Renal Cell Carcinoma Stage IV Renal Cell Cancer Recurrent Renal Cell Carcinoma

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Recombinant Interferon Alfa-2b
  • DRUG Sorafenib Tosylate

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2005-06
Est. Completion 2013-08
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00126594

The ClinicalTrials.gov registry entry for NCT00126594 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (60% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT00126594 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00126594 about?

NCT00126594 is a clinical study titled "Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer". This randomized phase II trial is studying sorafenib and interferon alfa-2b to see how well they work compared to sorafenib alone in treating patients with metastatic kidney cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2...

What is the current status of trial NCT00126594?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2005-06. Estimated completion is 2013-08.

What conditions does trial NCT00126594 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Carcinoma.

What interventions are being tested in trial NCT00126594?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Recombinant Interferon Alfa-2b (BIOLOGICAL), Sorafenib Tosylate (DRUG).

Who is sponsoring clinical trial NCT00126594?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00126594 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Clear Cell Renal Cell Carcinoma

All registered trials for this condition

Stage IV Renal Cell Cancer

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.